- Home
- RVSN vs CNSP Comparison
RVSN vs CNSP Comparison
Compare RVSN & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSN | CNSP |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 8.5M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RVSN | CNSP |
|---|---|---|
| Price | $3.10 | $4.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.6K | 3.3K |
| Earning Date | 08-26-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $169.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $1.90 |
| 52 Week High | $9.39 | $10.54 |
Technical Indicators
Market Signals| Indicator | RVSN | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 31.73 |
| Support Level | $0.24 | $3.90 |
| Resistance Level | $5.09 | $5.52 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 33.32 | 26.17 |
Price Performance
Historical ComparisonAbout RVSN Rail Vision Ltd.
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.